Elizabeth Holmes welcomes second child as she seeks to delay prison term

Theranos founder Elizabeth Holmes is now a mother of two, according to a court document filed last week, and she is attempting to put off her impending incarceration.

According to court documents that The Mercury News this week was able to obtain, the 39-year-old was given a sentence of more than 11 years in prison and is scheduled to start on April 27. However, she and her legal team want to delay that until the conclusion of her appeal.

Holmes is described in the documents as the mother of “two very young children.” Her boyfriend Billy Evans confirmed that she was pregnant with their second child in November. While awaiting trial for her accusations, Holmes gave birth to her first child in July 2021.

“Ms. Holmes has deep ties to the community: She is the mother of two very young children; she has close relationships with family and friends, many of who submitted letters at sentencing vouching for her good character; and she volunteers with a rape crisis and counseling organization,” the court filing read.

According to Mercury News, prosecutors contend that Holmes is a flight risk and shouldn’t be free past the day she is scheduled to report to prison, despite the defence team’s arguments to the contrary.

According to a Mercury News story, the appeals procedure for the former CEO of Theranos, who was found guilty of cheating investors out of more than $144 million in January 2022, might take up to two years to complete.

In a court document from November, Judge Edward Davila of the Northern District of California suggested that Holmes complete her term at the Federal Prison Camp in Bryan, Texas.

According to its website, the 37-acre campus of the minimum-security women’s jail, located about 100 miles northwest of Houston, is home to about 540 female offenders spread among four dormitory buildings.

Theranos was established in 2003 by Holmes, a Stanford University dropout. The goal of the Palo Alto-based firm was to perform blood tests that could identify a number of illnesses using only a small sample of blood.

Before Holmes and other Theranos executives were charged with fraud in 2018, the company’s valuation soared to $9 billion.